Sign in
Taking people in United StatesPhase 1/2

Pirtobrutinib for adults with immune thrombocytopenia, a low platelet condition

Tests pirtobrutinib against placebo in adults with immune thrombocytopenia.

Key facts

Who runs it
Eli Lilly and Company
Where
Austin, Houston, Los Angeles, Miami, New Orleans, Palo Alto, Peoria, Rochester, The Woodlands, and Washington D.C., United StatesSee the 10 sitesAlso in 9 other countries, 34 sites
Registry title
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Status
Recruiting
Phase
Phase 1/2
People taking part
68 people, planned
Started
30 Jul 2025
Expected to end
Feb 2029
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Pirtobrutinib
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. Their ITP must have come back or not responded to treatment.

Age
18 Years to 64 Years
Sex
All sexes can join.
Disease stage
Primary ITP that has come back or resists treatment, with no available therapies known to help. Low platelets not caused by another known disease.
Earlier treatment
At least 1 prior line of therapy that worked, with 2 or more platelet counts of 50,000/μL or more. Spleen removal (splenectomy) counts as a line of therapy. No blood transfusion, blood products or plasmapheresis within 14 days (Phase 1) or 28 days (Phase 2) before randomization.
Biomarker or test result
Platelet count less than 30,000/μL on 2 occasions at least 5 days apart in the 15 days before randomization. Liver, kidney and blood tests must be good enough, as set by the protocol.

Main reasons for not taking part

  • A blood clot or embolism within 12 months before screening
  • Serious heart or blood vessel disease
  • A current or past blood cancer
  • Hepatitis B infection (positive HBsAg or HBV DNA by PCR)
  • Hepatitis C infection (positive anti-HCV antibodies and HCV RNA by PCR)

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Have a diagnosis of primary ITP, defined as isolated thrombocytopenia not associated with another known disease process
  • Have documented history of response, defined as 2 or more platelet counts greater than or equal to 50,000/microliter (μL), to at least 1 prior line of therapy. Splenectomy is considered a line of therapy
  • Have relapsed or treatment-resistant primary ITP, with no available therapies known to provide clinical benefit
  • Have a platelet count less than 30,000/μL on 2 occasions at least 5 days apart in the 15 days before randomization
  • Have adequate liver, renal, and hematologic functions as defined by a table
  • Are willing to follow contraception requirements

Who cannot take part

  • Have a history of any thrombotic or embolic event within 12 months before screening
  • Have significant cardiovascular disease
  • Have a diagnosis or history of hematologic malignancy
  • Have hepatitis B virus (HBV) defined as positive for antigen of hepatitis B (HBsAg) or polymerase chain reaction (PCR) positive for HBV deoxyribonucleic acid (DNA)
  • Have hepatitis C virus (HCV) defined as positive for anti-HCV antibodies and PCR positive for HCV ribonucleic acid (RNA)
  • Had a transfusion with blood or blood products or plasmapheresis within 14 days (Phase 1) or within 28 days (Phase 2) of randomization

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in United States

Also in 9 other countries, 34 sites

  • Texas Oncology - Central SouthAustin, United StatesTaking people
  • MD Anderson Cancer CenterHouston, United StatesTaking people
  • USC / Norris Comprehensive Cancer CenterLos Angeles, United StatesTaking people
  • University of Miami Hospital and Clinics Sylvester Comprehensive Cancer CenterMiami, United StatesNot yet recruiting
  • Ochsner Clinic FoundationNew Orleans, United StatesTaking people
  • Stanford UniversityPalo Alto, United StatesTaking people
  • Bleeding and Clotting Disorders InstitutePeoria, United StatesNot yet recruiting
  • Mayo ClinicRochester, United StatesTaking people
  • Texas Oncology- Gulf CoastThe Woodlands, United StatesTaking people
  • MedStar Georgetown University HospitalWashington D.C., United StatesTaking people

About the trial

What the trial wants to find out

The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo.

Read full original descriptionShow less

The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.

The 3 groups in the trial

  • Pirtobrutinib Phase 1Treatment being tested

    Pirtobrutinib administered orally

    Treatment: Pirtobrutinib

  • Pirtobrutinib Phase 2Treatment being tested

    Pirtobrutinib administered orally

    Treatment: Pirtobrutinib

  • Placebo Phase 2Placebo, for comparison

    Placebo administered orally

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia
Plain-language title
Pirtobrutinib for adults with immune thrombocytopenia, a low platelet conditionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06721013, who can take part
Record updated
4 November 2026